



PATENT
Attorney Docket 059742-5001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David H. Wagner)	Confirmation No: 1193
)	
Application No. 10/563,570)	Group Art Unit: 1641
)	
Filed: August 25, 2006)	Examiner: Lisa V Cook
)	
For: Methods for Predicting Development of)	Date: July 23, 2007
Auto-Immune Diseases and Treatment)	
of Same)	

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Supplemental Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

The documents included in this Supplemental Information Disclosure Statement were cited in the Supplementary Partial European Search Report (dated May 22, 2007) for the corresponding European Patent application and in the PTO-892 form of the U. S. patent Application No. 11/399,384, a continuation-in-part application of the present application. A copy of the Supplementary Partial European Search Report is attached for the Examiner's convenience. With the exception of U.S. Patents, copies of

the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

Dated: July 23, 2007

MORGAN, LEWIS & BOCKIUS LLP

Morgan, Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue
Washington, D.C. 20004
Phone: (202)-739-3000

By: 
Sally P. Teng
Registration No. 45,397

